Various ongoing trials are also following this concept, and patients with ERlo breast cancer are being included in trials evaluating innovative therapies such as PARP inhibitors in combination with durvalumab (NCT 0359594369), the MEK inhibitor selumetinib (NCT01313039), and EGFR inhibitors. Here, MAP2K7 is linked to breast carcinoma.